Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.39 |
| ▸ | BRS3 | P32247 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26969753 | 0.89 | ACLY (0.41) | ACLYNOTUMHSD11B1ALDH1A1HDAC1 | |
| SCHEMBL26969780 | 0.87 | ACLY (0.44) | ACLYNOTUMNPC1L1NPY5R | |
| SCHEMBL30733401 | 0.85 | NOTUM (0.45) | ACLYNOTUMNPY5R | |
| SCHEMBL30733423 | 0.85 | KCNN4 (0.47) | ACLYNOTUMALDH1A1 | |
| SCHEMBL26969734 | 0.82 | MMP2 (0.44) | ACLYNOTUMALDH1A1HDAC1HDAC8 | |
| SCHEMBL25238614 | 0.81 | NOTUM (0.42) | ACLYNOTUMALDH1A1HDAC1HDAC8 | |
| SCHEMBL30733407 | 0.81 | AKR1B1 (0.47) | ACLYNOTUMNPY5R | |
| SCHEMBL25285056 | 0.81 | MMP2 (0.43) | ACLYNOTUMALDH1A1HDAC1HDAC8 | |
| SCHEMBL26969782 | 0.81 | NOTUM (0.41) | ACLYNOTUMALDH1A1HDAC1HDAC8 | |
| SCHEMBL26969767 | 0.81 | ALDH1A1 (0.49) | NOTUMALDH1A1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | ACLY 3265/4885NOTUM 2050/4885HSD11B1 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.